Biogen Idec Inc (BIIB)

pos +0.00
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,097,600
Last Update: 09/02/14 - 4:00 PM EDT
Volume: 0
YTD Performance: 22.57%
Open: $0.00
Previous Close: $342.68
52 Week Range: $213.05 - $358.89
Oustanding Shares: 236,144,705
Market Cap: 81,007,079,603
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 13 13
Moderate Buy 1 1 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.69 1.56 1.56
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 38.16
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
38.16 38.10 29.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.69% 60.87% 274.19%
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
Revenue 5.81B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $3.22 $3.41 $12.66 $16.06
Number of Analysts 2 2 2 2
High Estimate $3.53 $3.66 $13.13 $16.77
Low Estimate $2.91 $3.15 $12.20 $15.35
Prior Year $2.34 $2.33 $8.93 $12.66
Growth Rate (Year over Year) 37.61% 46.14% 41.83% 26.81%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Bionic or Just Plain? Real Money Pro($)

Checking two biotech charts.
Biotech stocks are thriving in a slower-growth, low-inflation world.

Recommended Viewing Real Money Pro($)

Take the ice bucket challenge?

Off the Charts Real Money Pro($)

As the action continues to the downside, we have no long positions on the table.

Off the Charts Real Money Pro($)

For the first time in months, we have no long positions on the table.
Jul 24, 2014 | 8:10 AM EDT
BIIB price target raised from $380 to $410, Jefferies said. Buy rating. Company beat estimates due to strong Tysabri and Tecfidera...
Jul 24, 2014 | 7:48 AM EDT
Shares of BIIB now seen reaching $425, according to Credit Suisse. Estimates also increased, as management guided to higher Tecfidera g...
In theory there should be plenty of shorting opportunities.
Too many people are willing to park cash in Microsoft or Apple.
McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

Columnist Conversations

I'm eyeing possible support in this one....writing about this tonight! View Chart &raq...
It was a quiet start to the week, in as much as the broader market was concerned. With only three trading day...
Market closes flat as oil & commodities take hit today on back of stronger dollar...something that could c...
Latest PAYX/IHS Small Business Jobs Index released today...Mountain region and Texas metro continue to lead th...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.